Live Stock Coverage: Time to Buy NewLink Genetics Corp After Today’s Big Increase?

Live Stock Coverage: Time to Buy NewLink Genetics Corp After Today's Big Increase?

The stock of NewLink Genetics Corp (NASDAQ:NLNK) is a huge mover today! About 159,014 shares traded hands. NewLink Genetics Corp (NASDAQ:NLNK) has declined 43.13% since April 5, 2016 and is downtrending. It has underperformed by 45.08% the S&P500.
The move comes after 8 months positive chart setup for the $293.63 million company. It was reported on Nov, 7 by We have $24.83 PT which if reached, will make NASDAQ:NLNK worth $349.42M more.

NewLink Genetics Corp (NASDAQ:NLNK) Ratings Coverage

Out of 2 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. NewLink Genetics has been the topic of 2 analyst reports since March 23, 2016 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Wednesday, March 23 by Robert W. Baird. The firm earned “Neutral” rating on Wednesday, May 11 by SunTrust.

According to Zacks Investment Research, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.”

Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.18, from 0.91 in 2016Q1. The ratio fall, as 34 funds sold all NewLink Genetics Corp shares owned while 32 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 14.35 million shares or 17.92% less from 17.49 million shares in 2016Q1.
Pnc Financial Serv Grp Inc Inc has 373 shares for 0% of their US portfolio. Eqis Cap Management owns 48,109 shares or 0.04% of their US portfolio. State Street Corporation accumulated 396,170 shares or 0% of the stock. Teacher Retirement Systems Of Texas accumulated 2,995 shares or 0% of the stock. Ubs Asset Mngmt Americas Incorporated owns 10,830 shares or 0% of their US portfolio. Northern Trust Corp owns 269,562 shares or 0% of their US portfolio. D E Shaw And Inc accumulated 0% or 26,284 shares. Renaissance Tech Ltd Limited Liability Company owns 815,500 shares or 0.02% of their US portfolio. Balyasny Asset Mgmt Ltd Liability last reported 75,000 shares in the company. Bancorp Of America Corp De last reported 0% of its portfolio in the stock. Quantitative Inv Ltd Liability Corp holds 0.03% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK) for 62,000 shares. Fifth Third Comml Bank owns 1,000 shares or 0% of their US portfolio. The New York-based Springbok Capital Mgmt Lc has invested 0% in NewLink Genetics Corp (NASDAQ:NLNK). Globeflex Capital L P accumulated 0.11% or 34,934 shares. State Bank Of New York Mellon Corp has 147,733 shares for 0% of their US portfolio.

More important recent NewLink Genetics Corp (NASDAQ:NLNK) news were published by: which released: “NewLink Genetics Corporation Provides Operational Update and Reports Third …” on November 01, 2016, also published article titled: “Why NewLink Genetics Shares Are Crashing 33% Today”, published: “Why NewLink Genetics Corporation Dropped 27.6% in May” on June 10, 2016. More interesting news about NewLink Genetics Corp (NASDAQ:NLNK) was released by: and their article: “NewLink Genetics Has Many Near-Term Catalysts” with publication date: September 27, 2016.

NLNK Company Profile

NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a biopharmaceutical firm focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. The Company’s biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. The Company’s additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additional product candidates are also under development for patients with other types of cancer. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod, which target key immune checkpoints. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment